LTPA2022524I1 - - Google Patents

Info

Publication number
LTPA2022524I1
LTPA2022524I1 LTPA2022524C LTPA2022524C LTPA2022524I1 LT PA2022524 I1 LTPA2022524 I1 LT PA2022524I1 LT PA2022524 C LTPA2022524 C LT PA2022524C LT PA2022524 C LTPA2022524 C LT PA2022524C LT PA2022524 I1 LTPA2022524 I1 LT PA2022524I1
Authority
LT
Lithuania
Prior art keywords
triptan
nsaid
present
layers
dissolution
Prior art date
Application number
LTPA2022524C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Nuvo Pharmaceuticals (Ireland) Designated Activity Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2022524(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nuvo Pharmaceuticals (Ireland) Designated Activity Company filed Critical Nuvo Pharmaceuticals (Ireland) Designated Activity Company
Publication of LTPA2022524I1 publication Critical patent/LTPA2022524I1/lt
Publication of LTC1575566I2 publication Critical patent/LTC1575566I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Waveguide Aerials (AREA)
LTPA2022524C 2002-12-26 2022-11-10 LTC1575566I2 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43600002P 2002-12-26 2002-12-26
PCT/US2003/040954 WO2004060355A1 (en) 2002-12-26 2003-12-22 Multilayer Dosage Forms Containing NSAIDs and Triptans

Publications (2)

Publication Number Publication Date
LTPA2022524I1 true LTPA2022524I1 (cg-RX-API-DMAC7.html) 2022-12-12
LTC1575566I2 LTC1575566I2 (cg-RX-API-DMAC7.html) 2023-08-10

Family

ID=32713052

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2022524C LTC1575566I2 (cg-RX-API-DMAC7.html) 2002-12-26 2022-11-10

Country Status (17)

Country Link
US (1) US7332183B2 (cg-RX-API-DMAC7.html)
EP (1) EP1575566B1 (cg-RX-API-DMAC7.html)
JP (1) JP4616009B2 (cg-RX-API-DMAC7.html)
AT (1) ATE546134T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003303631B2 (cg-RX-API-DMAC7.html)
CA (1) CA2509023C (cg-RX-API-DMAC7.html)
CY (1) CY1112640T1 (cg-RX-API-DMAC7.html)
DK (1) DK1575566T3 (cg-RX-API-DMAC7.html)
ES (1) ES2380827T3 (cg-RX-API-DMAC7.html)
HU (1) HUS2200049I1 (cg-RX-API-DMAC7.html)
IL (1) IL169041A (cg-RX-API-DMAC7.html)
LT (1) LTC1575566I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA05006954A (cg-RX-API-DMAC7.html)
NO (2) NO336458B1 (cg-RX-API-DMAC7.html)
PT (1) PT1575566E (cg-RX-API-DMAC7.html)
SI (1) SI1575566T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004060355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101687094B (zh) * 2005-09-06 2012-09-26 谢拉杰克特股份有限公司 含有药物颗粒和/或药物吸附颗粒的固体溶液穿孔器
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CN100358523C (zh) * 2006-01-24 2008-01-02 杭州民生药业集团有限公司 一种氨酚伪麻那敏口腔崩解片的制备方法
US20070207200A1 (en) * 2006-03-06 2007-09-06 Pozen Inc. Dosage forms for administering combinations of drugs
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
AU2007267612A1 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2008049116A2 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
DE602007005402D1 (de) * 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
GB0625646D0 (en) * 2006-12-21 2007-01-31 Jagotec Ag Improvements in or relating to organic compounds
BRPI0700133A (pt) * 2007-01-29 2008-09-16 Incrementha P D & I Pesquisa D composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
CA2677623C (en) 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
JP2008201712A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd フィルムコーティング製剤
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
GB0714790D0 (en) * 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20090186086A1 (en) * 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
US20110118189A1 (en) * 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
AU2009260166B2 (en) * 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
US20100008986A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Pharmaceutical compositions comprising sumatriptan and naproxen
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
US8377475B2 (en) * 2009-01-05 2013-02-19 Mcneil-Ppc, Inc. Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
US8246988B2 (en) * 2009-01-05 2012-08-21 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
WO2010078541A1 (en) * 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CN102276447B (zh) * 2011-06-03 2013-11-20 海南锦瑞制药股份有限公司 一种萘普生水合物晶体、其制备方法及含有该晶体和舒马普坦的药用组合物
CA2850952A1 (en) * 2011-10-28 2013-05-02 Sung-Yun Kwon Dissolving solid solution perforator patch for migraine treatment
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
WO2015148271A1 (en) * 2014-03-26 2015-10-01 Vivid Pharma, Inc. Compositions for treating or preventing alcohol-induced symptoms
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12485176B2 (en) 2015-02-10 2025-12-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3565550T3 (da) 2017-01-04 2021-01-18 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12691123B2 (en) 2017-06-29 2026-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
TR201720429A2 (tr) 2017-12-15 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Flurbi̇profen ve 5-ht1&#8211#&reseptör agoni̇stleri̇ni̇n farmasöti̇k kompozi̇syonlari
US20240058354A1 (en) 2020-04-06 2024-02-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12128052B2 (en) 2020-05-28 2024-10-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12370196B2 (en) 2020-12-31 2025-07-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20230125826A (ko) 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12544383B1 (en) 2025-01-30 2026-02-10 Axsome Therapeutics, Inc. Methods of treating migraines with a combination of a meloxicam and a rizatriptan

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701438A (en) * 1902-02-10 1902-06-03 Schieffelin And Company Compressed tablet.
NL109293C (cg-RX-API-DMAC7.html) * 1955-12-22
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
US3358687A (en) * 1965-12-06 1967-12-19 Sterling Drug Inc Suppositories
IL45357A (en) * 1974-07-26 1978-04-30 Yeda Res & Dev Pharmaceutical compositions comprising aromatic amino acids as inhibitors of prostaglandin action
GR79215B (cg-RX-API-DMAC7.html) * 1982-06-07 1984-10-22 Glaxo Group Ltd
FR2539989B1 (fr) 1983-01-28 1985-08-09 Sanofi Sa Medicament a liberation programmee associant l'acide acetylsalicylique a la dihydroergotamine
GB2135884B (en) 1983-03-09 1986-09-17 Sandoz Ltd Analgesic preparations containing tizanidine and paracetamol
GB2162522B (en) 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
US4786500A (en) * 1986-06-26 1988-11-22 Alza Corporation Programmable agent delivery system
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
HUT57185A (en) 1990-03-21 1991-11-28 Merrell Dow Pharma Process for producing 8-sulfamil-methylen-2-amino-tetraline derivatives and pharmaceutical compositions containing them
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
CS277525B6 (en) 1990-12-27 1993-03-17 Pavel Rndr Rac Mixture against migraine
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
GB9125699D0 (en) * 1991-12-03 1992-01-29 Glaxo Group Ltd Device
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
BE1006861A6 (nl) * 1992-04-15 1995-01-10 Picanol Nv Weefmachine voorzien van een zelfkantinrichting.
IT1258143B (it) * 1992-09-11 1996-02-20 Alfa Wassermann Spa Compresse a cessione programmata contenenti naproxen
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
KR960701865A (ko) * 1993-04-22 1996-03-28 데이비드 존. 우드 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
DE4314976C1 (de) 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5514168A (en) * 1994-05-20 1996-05-07 Friedman; Mark H. Treatment of vascular headache and atypical facial pain
US5698571A (en) 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US5618816A (en) * 1995-03-02 1997-04-08 Bristol-Myers Squibb Company Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines
DE19542281C2 (de) 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
AU2890899A (en) 1998-03-13 1999-09-27 Pozen, Inc. Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
ES2234324T3 (es) 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
ES2194536T3 (es) * 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) * 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
AU3596500A (en) 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
IL136023A0 (en) 1999-05-14 2001-05-20 Pfizer Prod Inc 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
CO5261541A1 (es) 1999-05-14 2003-03-31 Pfizer Prod Inc Terapia de combinacion para el tratamiento de la migrana
JP3796562B2 (ja) * 1999-05-26 2006-07-12 ライオン株式会社 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法
CO5190678A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
IL136961A0 (en) 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
US20020099059A1 (en) * 2000-08-23 2002-07-25 Joel Saper Combination therapy for the treatment of migraine
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US20030203027A1 (en) * 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica

Also Published As

Publication number Publication date
JP2006515856A (ja) 2006-06-08
NO20053193D0 (no) 2005-06-29
NO2022045I1 (en) 2022-11-02
EP1575566A1 (en) 2005-09-21
US20040180089A1 (en) 2004-09-16
CA2509023C (en) 2011-05-24
AU2003303631B2 (en) 2008-05-29
ATE546134T1 (de) 2012-03-15
ES2380827T3 (es) 2012-05-18
HUS2200049I1 (hu) 2022-12-28
CA2509023A1 (en) 2004-07-22
PT1575566E (pt) 2012-03-29
WO2004060355A1 (en) 2004-07-22
AU2003303631A1 (en) 2004-07-29
SI1575566T1 (sl) 2012-08-31
LTC1575566I2 (cg-RX-API-DMAC7.html) 2023-08-10
NO336458B1 (no) 2015-08-31
JP4616009B2 (ja) 2011-01-19
EP1575566A4 (en) 2007-05-09
MXPA05006954A (es) 2005-09-22
IL169041A (en) 2012-05-31
DK1575566T3 (da) 2012-03-26
US7332183B2 (en) 2008-02-19
CY1112640T1 (el) 2016-02-10
NO20053193L (no) 2005-09-08
EP1575566B1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
LTC1575566I2 (cg-RX-API-DMAC7.html)
SI1467712T1 (sl) Dvoplastna farmacevtska tableta, ki obsega telmisartan in hidroklorotiazid
TWI350184B (en) High drug load tablet
ATE456368T1 (de) Reboxetin enthaltende tablette mit verzögerter wirkstoffabgabe
PT1727551E (pt) Composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteína de fusão do rsv
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
GEP20105083B (en) A solid pharmaceutical dosage formulation
PH12012501539B1 (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
GEP20074047B (en) Pramipexole once-daily dosage form
ATE431138T1 (de) Deferasirox dispergierbare tablette
AR033467A1 (es) Comprimido de meloxicam de rapida disgregacion
AR038206A1 (es) Composicion farmaceutica dispersable oralmente de ivabradina
AU2003265817A1 (en) Effervescent hop tablet
ZA200410156B (en) Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
ATE471713T1 (de) Tablette enthaltend fluvastatin und calciumcarmellose
ITBO20020452A0 (it) Macchina comprimitrice
IL181183A0 (en) Enzyme inhibitor in leukemia
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AU2003287388A1 (en) Inhibition of hiv-1 replication
AU2003282086B2 (en) Multi-layer transmucosal therapeutic system
GB0225141D0 (en) Usis of prolyl oligopeptidase inhibitors
HK1078260A (en) Multicomponent pharmaceutical dosage form
HK1071693A (en) Progestagenic dosage units
AR025576A1 (es) Preparacion farmaceutica para hipertension arterial